Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: Fierce 15 nominations are now open! We're looking for the best and brightest in biotech.
Biotech
Biotech
Gilead liver disease med still delivers ahead of FDA verdict
Three months after spending $4.3 billion on CymaBay for its primary biliary cholangitis med, Gilead Sciences has presented a fresh slice of data.
James Waldron
May 20, 2024 8:30am
Fierce Biotech Layoff Tracker '24: Erasca, Akari & more
May 20, 2024 8:00am
Sponsored
Patient Access and Affordability: PhRMA shares how we can put patients first
Feb 12, 2024 8:00am
Endeavor links IPF drug to improved lung function in phase 2
May 20, 2024 5:55am
Sponsored
Cognizant & Takeda Discuss Digital Transformation in Lifescience
Feb 12, 2024 8:00am
Third Rock, J&J neuroscience spinout Rapport outlines IPO plans
May 20, 2024 5:13am